• Christina E DeRemer, Eric A Dietrich, Hye-Rim Kang, Pei-Lin Huang, Wei-Hsuan Lo-Ciganic, and Haesuk Park.
• Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
• J. Intern. Med. 2022 Jun 1; 291 (6): 877-885.

BackgroundThe optimal dose of apixaban therapy to prevent asecondary venous thromboembolism (VTE) event remains unconfirmed. To investigate the effects of extended phase use of apixaban (2.5 vs. 5 mg twice daily) beyond 6 months of initial treatment on the risk of recurrent VTE and major bleeding events among patients with a history of VTE.MethodsA retrospective cohort analysis of two large national insurance claims databases was conducted for patients diagnosed with VTE. Cox proportional hazard models after propensity score matching were used to compare the risk of recurrent VTE and major bleeding.ResultsThere were no detected differences in recurrent VTE or major bleeding events between patients prescribed low versus full dose apixaban.ConclusionThis study provides evidence that apixaban 2.5 mg twice daily is an alternative option for extended phase therapy for risk reduction of VTE recurrence compared to apixaban 5 mg twice daily.© 2022 The Association for the Publication of the Journal of Internal Medicine.

17 keywords...

hide…